Posted On: 08/03/2014 3:49:46 PM
Post# of 273366
Aes Tiete Sa (AESYY) 8.2200 $AESYY
Quest Diagnostics Expands Hereditary Cancer Screening Offering with Lynch Syndrome Blood and Biopsy Testing for Colorectal Cancer
PR Newswire - Wed Feb 26, 8:00AM CST
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced new pathology and blood test offerings to help identify and assess an individual's risk of Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), an inherited genetic disorder that significantly increases the risk of colorectal and other cancers.
AES Tiete's Net Income Comes To R$185.7 Million In 1Q13
PR Newswire - Wed May 08, 9:28PM CDT
AES Tiete S.A. (BM&FBovespa: GETI3 and GETI4; OTC: AESAY and AESYY) announced today its 1Q13 results.
Quest Diagnostics Expands Hereditary Cancer Screening Offering with Lynch Syndrome Blood and Biopsy Testing for Colorectal Cancer
PR Newswire - Wed Feb 26, 8:00AM CST
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced new pathology and blood test offerings to help identify and assess an individual's risk of Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), an inherited genetic disorder that significantly increases the risk of colorectal and other cancers.
AES Tiete's Net Income Comes To R$185.7 Million In 1Q13
PR Newswire - Wed May 08, 9:28PM CDT
AES Tiete S.A. (BM&FBovespa: GETI3 and GETI4; OTC: AESAY and AESYY) announced today its 1Q13 results.
(0)
(0)
